RPHCF (Rohto Pharmaceutical Co) Cyclically Adjusted Revenue per Share: $6.69 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RPHCF Rohto Pharmaceutical Co Ltd RPHCF
89 GF Score
Price $15.00
GF Value $21.04
! 2 Warning Signs
View Full Analysis

What is Rohto Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Rohto Pharmaceutical Co RPHCF 89 Cyclically Adjusted Revenue per Share is $6.69 as of Mar. 2026. GuruFocus rates RPHCF with a GF Score™ of 89/100 and a GF Value™ of $21.04. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Rohto Pharmaceutical Co's adjusted revenue per share for the three months ended in Mar. 2026 was $2.424. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $6.69 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Rohto Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was 8.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Rohto Pharmaceutical Co was 9.50% per year. The lowest was 4.70% per year. And the median was 7.15% per year.

As of today (2026-07-22), Rohto Pharmaceutical Co's current stock price is $15.00. Rohto Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $6.69. Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 2.24.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Rohto Pharmaceutical Co was 4.86. The lowest was 1.94. And the median was 2.49.


Rohto Pharmaceutical Co  (OTCPK:RPHCF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=15.00/6.69
=2.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Rohto Pharmaceutical Co was 4.86. The lowest was 1.94. And the median was 2.49.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Rohto Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Rohto Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Rohto Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rohto Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Rohto Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.04 5.09 6.14 8.81 6.69

Rohto Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.81 7.23 6.05 6.50 6.69

RPHCF vs PG, CL, KVUE: Cyclically Adjusted Revenue per Share Comparison

For the Household & Personal Products subindustry, Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rohto Pharmaceutical Co Cyclically Adjusted PS Ratio vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Rohto Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


RPHCF
89GF Score
Rohto Pharmaceutical Co Ltd RPHCF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rohto Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Rohto Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.424/112.7000*112.7000
=2.424

Current CPI (Mar. 2026) = 112.7000.

Rohto Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.370 98.100 1.574
201609 1.648 98.000 1.895
201612 1.509 98.400 1.728
201703 1.673 98.100 1.922
201706 1.415 98.500 1.619
201709 1.679 98.800 1.915
201712 1.763 99.400 1.999
201803 1.969 99.200 2.237
201806 1.614 99.200 1.834
201809 1.816 99.900 2.049
201812 1.849 99.700 2.090
201903 1.926 99.700 2.177
201906 1.693 99.800 1.912
201909 1.973 100.100 2.221
201912 1.909 100.500 2.141
202003 2.044 100.300 2.297
202006 1.575 99.900 1.777
202009 1.834 99.900 2.069
202012 1.963 99.300 2.228
202103 2.066 99.900 2.331
202106 1.680 99.500 1.903
202109 1.932 100.100 2.175
202112 2.035 100.100 2.291
202203 2.051 101.100 2.286
202206 1.705 101.800 1.888
202209 1.771 103.100 1.936
202212 2.136 104.100 2.312
202303 2.041 104.400 2.203
202306 1.891 105.200 2.026
202309 1.972 106.200 2.093
202312 2.225 106.800 2.348
202403 2.032 107.200 2.136
202406 1.893 108.200 1.972
202409 2.162 108.900 2.237
202412 2.467 110.700 2.512
202503 2.424 111.100 2.459
202506 2.511 111.700 2.533
202509 2.406 112.000 2.421
202512 2.440 113.000 2.434
202603 2.424 112.700 2.424

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $6.69 mean?
Rohto Pharmaceutical Co (RPHCF) has a Cyclically Adjusted Revenue per Share of $6.69 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Rohto Pharmaceutical Co and its competitors.
Is Rohto Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Rohto Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is $6.69. Overall, Rohto Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Rohto Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to PG and CL?
Rohto Pharmaceutical Co's Cyclically Adjusted Revenue per Share of $6.69 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Consumer Packaged Goods company?
A good Cyclically Adjusted Revenue per Share depends on the Consumer Packaged Goods industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Rohto Pharmaceutical Co and its competitors. Rohto Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is $6.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rohto Pharmaceutical Co stock overvalued right now?
Rohto Pharmaceutical Co (RPHCF) has a current Cyclically Adjusted Revenue per Share of $6.69. The stock's GF Value™ is $21.04, compared to a current price of $15.00 — trading 28.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $6.69. Rohto Pharmaceutical Co's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Rohto Pharmaceutical Co (RPHCF), the current Cyclically Adjusted Revenue per Share is $6.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rohto Pharmaceutical Co (RPHCF) Overvalued in 2026?

Based on GuruFocus' analysis, Rohto Pharmaceutical Co stock appears to be undervalued. The current stock price of $15.00 is trading 28.7% below its estimated GF Value™ of $21.04.

Key valuation signals for RPHCF:

  • Cyclically Adjusted Revenue per Share: $6.69
  • GF Value™: $21.04 vs. price of $15.00 (28.7% below fair value)
  • GF Score™: 89/100 with 2 warning signs

No single metric tells the full story. See the RPHCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Rohto Pharmaceutical Co Business Description

Other Exchanges 4527:Japan
Address 1-8-1 Tatsuminishi, Ikuno-ku, Osaka, JPN, 544-8666
Rohto Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of health and beauty care products. The company operates through four reportable segments: Japan, America, Europe, and Asia. Each segment manufactures and sells products related to eye care (such as eye drops and eyewash), skin care (including dermatological medications, lip balm, sunscreen, and functional cosmetics), oral medication (such as gastrointestinal and herbal medicines, and supplements), and other products such as in-vitro diagnostic reagents. It generates the majority of its revenue from Japan.
89GF Score

Get the complete analysis for RPHCF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.00
Price
$21.04
GF Value